Artelo Files Patent, Launches Preclinical Study for ART27.13 to Protect Muscle in GLP-1 Patients
Artelo Biosciences filed a provisional patent and launched a non-clinical study to develop ART27.13 for preserving lean body mass in patients on GLP-1 agonists. CAReS trial data showed the highest-dose cohort gained about 6% weight with activity gains versus 5% weight loss on placebo.
1. Muscle Preservation Data
Interim CAReS trial results showed that patients receiving the highest dose of ART27.13 experienced an average 6% weight gain and improved activity levels, compared to a 5% weight loss in the placebo group, demonstrating a potential protective effect against muscle loss.
2. Patent Filing and Non-Clinical Study
Artelo Biosciences filed a provisional patent application covering the use of CB2 agonism to prevent or mitigate muscle loss associated with GLP-1 therapy, and has initiated a non-clinical study to evaluate ART27.13 in relevant GLP-1 muscle preservation models.
3. Independent Pharmacology Validation
Peer-reviewed research characterized ART27.13 as a CB2 superagonist with differentiated pharmacology compared to 16 other clinically studied agonists, supporting its potential utility as a companion therapy for GLP-1 treatments.
4. Market Opportunity for GLP-1 Companion Therapy
Rapid growth in GLP-1 prescriptions—projected to reach 25 million U.S. patients and a $200 billion global market by 2030—highlights significant unmet needs for lean body mass preservation, positioning ART27.13 for potential commercial relevance.